IGM Biosciences, Inc.
USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER

Abstract:

This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a chemotherapeutic agent, e.g., a type I topoisomerase inhibitor, a nucleoside analog, or a pro-apoptotic agent, e.g., a BCL-2 inhibitor.